Embecta (EMBC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
23 Jan, 2026Voting matters and shareholder proposals
Proposal 4 seeks approval to amend the 2022 Employee and Director Equity-Based Compensation Plan, increasing available shares by 2,430,000, as approved by the Board on December 2, 2025.
Institutional Shareholder Services (ISS) recommended voting against the amendment, citing that the stockholder value transfer (SVT) exceeded ISS benchmarks based on a September 30, 2025 calculation date.
The company argues that using a November 30, 2025 calculation date aligns the plan with ISS guidelines and provides updated share activity data to support this.
The Board maintains its recommendation to vote in favor of Proposal 4.
Executive compensation and say-on-pay
The amendment to the 2022 Plan is intended to ensure sufficient equity incentives for employees and directors, with updated figures on outstanding awards and share reserves.
Outstanding performance share units (PSUs) include awards with targets to be established in the future, reflecting ongoing performance-based compensation practices.
Board of directors and corporate governance
The Board approved the proposed amendment to the equity plan on December 2, 2025, demonstrating active oversight of compensation policies.
Latest events from Embecta
- Profitability and margins improved despite lower revenue, with restructuring and debt reduction ongoing.EMBC
Q2 20259 Jul 2026 - Revenue was stable at $261.2M, with net income up and guidance reaffirmed.EMBC
Q1 20268 Jul 2026 - Margins and adjusted EPS guidance raised as operational execution offsets revenue decline.EMBC
Q3 20248 Jul 2026 - Profitability and margins improved despite revenue decline, with strong cash flow and debt reduction.EMBC
Q4 20258 Jul 2026 - Diversification and the Owen Mumford deal position the company for growth beyond insulin delivery.EMBC
Bank of America Global Healthcare Conference 202613 May 2026 - Q2 revenue fell 14.4% as U.S. weakness drove lower guidance and a major acquisition.EMBC
Q2 20265 May 2026 - Transformation to a diversified medical supplies leader, targeting growth via GLP-1 and new markets.EMBC
Investor Day 20253 Feb 2026 - Pen needle growth, GLP-1 tailwinds, and patch pump innovation drive a stable outlook.EMBC
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Open loop pump cleared; closed-loop focus, stable pen needle business, and improving cash flow.EMBC
CL King's 22nd Annual Best Ideas Conference 202420 Jan 2026